Dofetilide use is not associated with increased mortality in patients with left ventricular hypertrophy and atrial fibrillation.
Tikosyn
antiarrhythmic
atrial fibrillation
class III
dofetilide
left ventricular hypertrophy
Journal
Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
revised:
25
09
2022
received:
09
09
2022
accepted:
17
10
2022
pubmed:
7
11
2022
medline:
11
2
2023
entrez:
6
11
2022
Statut:
ppublish
Résumé
Left ventricular hypertrophy (LVH) is common in patients with atrial fibrillation (AF), however, many antiarrhythmic drugs (AADs) are contraindicated. US guidelines recommend avoiding pure class III antiarrhythmics such as dofetilide in patients with significant LVH due to concern for an increased risk of death, however, clinical data is lacking. We sought to determine if dofetilide use was associated with increased mortality in patients with LVH. Patients ≥18 years of age with AF and LVH ≥ 1.4 cm were included. A group of patients treated with dofetilide and a control group of patients without a history of AAD use were propensity matched. The primary outcome was all-cause mortality at 3 years and secondary outcomes were total number of all-cause hospitalizations and hospitalizations related to AF. There were 359 patients in each of the groups. Baseline variables were well-matched. The primary outcome of all-cause mortality occurred in 7% of patients in the dofetilide group and 12% of patients in the control group (hazard ratio: 0.90, 95% confidence interval: 0.53-1.53). Total all-cause hospitalizations were higher in the control group but hospitalizations for AF were no different. In a propensity-matched cohort of 718 patients with AF and LVH, dofetilide was not associated with increased mortality at 3 years. Our study adds to prior data demonstrating the safety of dofetilide in this population despite guideline recommendations against its use. Given the limited options for AF management in LVH patients, dofetilide may be reasonable for symptomatic AF management.
Sections du résumé
BACKGROUND
Left ventricular hypertrophy (LVH) is common in patients with atrial fibrillation (AF), however, many antiarrhythmic drugs (AADs) are contraindicated. US guidelines recommend avoiding pure class III antiarrhythmics such as dofetilide in patients with significant LVH due to concern for an increased risk of death, however, clinical data is lacking. We sought to determine if dofetilide use was associated with increased mortality in patients with LVH.
METHODS
Patients ≥18 years of age with AF and LVH ≥ 1.4 cm were included. A group of patients treated with dofetilide and a control group of patients without a history of AAD use were propensity matched. The primary outcome was all-cause mortality at 3 years and secondary outcomes were total number of all-cause hospitalizations and hospitalizations related to AF.
RESULTS
There were 359 patients in each of the groups. Baseline variables were well-matched. The primary outcome of all-cause mortality occurred in 7% of patients in the dofetilide group and 12% of patients in the control group (hazard ratio: 0.90, 95% confidence interval: 0.53-1.53). Total all-cause hospitalizations were higher in the control group but hospitalizations for AF were no different.
CONCLUSIONS
In a propensity-matched cohort of 718 patients with AF and LVH, dofetilide was not associated with increased mortality at 3 years. Our study adds to prior data demonstrating the safety of dofetilide in this population despite guideline recommendations against its use. Given the limited options for AF management in LVH patients, dofetilide may be reasonable for symptomatic AF management.
Substances chimiques
Anti-Arrhythmia Agents
0
Phenethylamines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
447-452Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Ball J, Carrington MJ, McMurray JJV, Stewart S. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol. 2013;167(5):1807-1824. doi:10.1016/j.ijcard.2012.12.093
January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071-2104. doi:10.1161/CIR.0000000000000040
Eguchi K, Boden-Albala B, Jin Z, et al. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol. 2008;101(12):1787-1791. doi:10.1016/j.amjcard.2008.02.082
Drazner MH. The progression of hypertensive heart disease. Circulation. 2011;123(3):327-334. doi:10.1161/CIRCULATIONAHA.108.845792
Chatterjee S, Bavishi C, Sardar P, et al. Meta-analysis of left ventricular hypertrophy and sustained arrhythmias. Am J Cardiol. 2014;114(7):1049-1052. doi:10.1016/j.amjcard.2014.07.015
Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol. 1987;60(7):560-565. doi:10.1016/0002-9149(87)90305-5
Siegel D, Cheitlin MD, Black DM, Seeley D, Hearst N, Hulley SB. Risk of ventricular arrhythmias in hypertensive men with left ventricular hypertrophy. Am J Cardiol. 1990;65(11):742-747. doi:10.1016/0002-9149(90)91381-f
Margey R, Roy A, Tobin S, et al. Sudden cardiac death in 14- to 35-year olds in Ireland from 2005 to 2007: a retrospective registry. Europace. 2011;13(10):1411-1418. doi:10.1093/europace/eur161
Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol. 1998;32(5):1454-1459. doi:10.1016/s0735-1097(98)00407-0
Oikarinen L, Nieminen MS, Viitasalo M, et al. Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. J Hypertens. 2001;19(10):1883-1891. doi:10.1097/00004872-200110000-00025
Panikkath R, Reinier K, Uy-Evanado A, et al. Electrocardiographic predictors of sudden cardiac death in patients with left ventricular hypertrophy. Ann Noninvasive Electrocardiol. 2013;18(3):225-229. doi:10.1111/anec.12003
Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med. 2007;356(9):935-941. doi:10.1056/NEJMct065916
Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365(24):2268-2276. doi:10.1056/NEJMoa1109867
Kober L, Torp-Pedersen C, McMurray JJV, et al, for the dronedarone study groupIncreased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678-2687.
Aktas MK, Shah AH, Akiyama T. Dofetilide-induced long QT and torsades de pointes. Ann Noninvasive Electrocardiol. 2007;12(3):197-202. doi:10.1111/j.1542-474X.2007.00161.x
Brumberg G, Gera N, Pray C, et al. Frequency of toxicity with chemical conversion of atrial fibrillation with dofetilide. Am J Cardiol. 2013;112(4):505-508. doi:10.1016/j.amjcard.2013.04.014
Abraham JM, Saliba WI, Vekstein C, et al. Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter. Circulation: Arrhythmia and Electrophysiology. 2015;8(4):772-776. doi:10.1161/CIRCEP.114.002339
Moore JC, Trager L, Anzia LE, et al. Dofetilide for suppression of atrial fibrillation in hypertrophic cardiomyopathy: a case series and literature review. Pacing Clin Electrophysiol. 2018;41(4):396-401. doi:10.1111/pace.13310
Chung R, Houghtaling PL, Tchou M, et al. Left ventricular hypertrophy and antiarrhythmic drugs in atrial fibrillation: impact on mortality. Pacing Clin Electrophysiol. 2014;37(10):1338-1348. doi:10.1111/pace.12426